20/05/2022

Related Posts

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
Read More
STADA delivers double-digit growth in 2019 as it invests to lead Consumer Healthcare and Generics core segments
STADA delivers double-digit growth in 2019 as it invests to lead Consumer Healthcare and Generics core segments
Read More
Corona Survey
Corona Survey
Insights into how people in four major European countries are feeling about healthcare issues amid the COVID-19 crises.
Read More
Zoflora® Oilatum® Sinulan Allergy Forte Sinulan Express Forte Stadent
About STADA About our products Contact
Contact +6620597420
FOLLOW US
© Copyright STADA Arzneimittel AG